Bimagrumab


Anti-activin receptor type II monoclonal antibody

A humanized monoclonal antibody against activin receptor type II; investigated for sarcopenia, sIBM, and obesity-related muscle preservation.

Abstract

Bimagrumab (BYM338; humanized IgG1 monoclonal antibody; molecular weight approximately 145 kDa) is a humanized monoclonal antibody against activin receptor type II (ActRII), developed at MorphoSys and Novartis. The compound binds ActRIIA and ActRIIB receptors on the cell surface, blocking access by myostatin, activin A, and GDF-11; the receptor-level blockade is mechanistically distinct from ligand traps (ACE-031) and from selective myostatin antibodies (stamulumab). Phase 2 trials in sporadic inclusion body myositis (RESILIENT) and sarcopenia demonstrated muscle mass increases. The compound generated substantial interest in 2020 after a phase 2 trial in obesity with type 2 diabetes (BIM-T2D) showed approximately 21 percent reduction in fat mass with concurrent muscle preservation, an unusual profile that has subsequently driven obesity-related development. Used as a research probe for receptor-level myostatin pathway inhibition.

FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human or animal consumption. All information is provided for research and educational purposes only.


Browse all monographs

Previous monograph
Next monograph